Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHAPSODY: INCMGA00012 as consolidation after chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
KCT0004857Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Incyte. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
retifanlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on KCT0004857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004857.